BR100 Decreased By (-0.15%)
BR30 Decreased By (-0.74%)
KSE100 Decreased By (-0.41%)
KSE30 Decreased By (-0.67%)
BECO 5.80 Decreased By ▼ -0.23 (-3.81%)
BML 58.03 Increased By ▲ 5.28 (10.01%)
BOP 33.85 Decreased By ▼ -0.40 (-1.17%)
CNERGY 8.15 Decreased By ▼ -0.01 (-0.12%)
DCL 11.77 Decreased By ▼ -0.57 (-4.62%)
FCCL 53.35 Decreased By ▼ -0.54 (-1%)
FCSC 5.40 Increased By ▲ 0.18 (3.45%)
FFL 17.89 Decreased By ▼ -0.14 (-0.78%)
FNEL 1.31 Increased By ▲ 0.01 (0.77%)
HUMNL 11.06 Increased By ▲ 0.06 (0.55%)
KEL 8.05 Decreased By ▼ -0.06 (-0.74%)
KOSM 5.45 Increased By ▲ 0.07 (1.3%)
MLCF 87.19 Decreased By ▼ -0.86 (-0.98%)
NBP 184.60 Decreased By ▼ -1.88 (-1.01%)
PACE 11.62 Increased By ▲ 0.90 (8.4%)
PAEL 40.31 Increased By ▲ 0.37 (0.93%)
PIAHCLA 26.10 Decreased By ▼ -0.07 (-0.27%)
PIBTL 17.09 Decreased By ▼ -0.23 (-1.33%)
PPL 228.40 Decreased By ▼ -4.38 (-1.88%)
PRL 34.59 Decreased By ▼ -0.36 (-1.03%)
PTC 67.35 Decreased By ▼ -0.21 (-0.31%)
SEARL 91.00 Increased By ▲ 0.07 (0.08%)
SSGC 26.90 Decreased By ▼ -0.27 (-0.99%)
TELE 8.53 Decreased By ▼ -0.04 (-0.47%)
THCCL 66.14 Increased By ▲ 6.01 (10%)
TPLP 9.29 Increased By ▲ 0.53 (6.05%)
TREET 24.59 Increased By ▲ 0.05 (0.2%)
TRG 71.69 Decreased By ▼ -0.06 (-0.08%)
WAVES 10.98 Increased By ▲ 1.00 (10.02%)
WTL 1.28 Increased By ▲ 0.02 (1.59%)
اردو
Android App
Print Edition Dollar to PKR
Budget 2026-27 Iran-US war Petrol Prices Gold Rates Podcasts PSX Notices
Business & Finance

Brazil health regulator eyes import of AstraZeneca vaccine from India

  • Based on the data presented by Brazilian biomedical center Fiocruz, along with more information to be presented by the Serum Institute of India.
Published January 4, 2021 Updated January 4, 2021 09:35pm
Save
1 min
comment
By Reuters
Add BRecorder as a trusted
source on Google
Google Preferred Source

BRASILIA: Brazilian health regulator Anvisa has received data regarding the AstraZeneca COVID-19 vaccine being produced in India from the vaccine maker's partners in Brazil, the agency said in a statement on Monday.

Based on the data presented by Brazilian biomedical center Fiocruz, along with more information to be presented by the Serum Institute of India, Anvisa said it will evaluate how comparable the vaccine is to the shot produced in the U.K. before it decides on possible approval for emergency use.

Anvisa AstraZeneca vaccine

Comments

Comments are closed for this article.

More Stories

Browse all stories